Sai Life Sciences block deal: 10% equity changes hands, TPG Asia likely seller

Sai Life Sciences shares settled one percent lower on June 19, 2025.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Sai Life Sciences were flat on Friday, June 20, as private equity firm TPG Asia likely divested a significant portion of its stake in the firm through the block deal route.

Around 2.08 crore shares, which equals around 10 percent equity, were exchanged in the block deal window, ahead of the opening bell.

Earlier, reports noted that the stake sale would involve 1.25 crore shares, but the deal has likely been upsized to 2 crore shares. The base price is expected to be around Rs 710 per share, which would represent a 2.5 percent discount to the previous session's closing price.

Following the block deal, TPG Asia will have a 60-day lock-in period, where it can't sell anymore Sai Life Sciences shares.

Follow our live blog to catch all the market updates

Sources added that TPG Asia is the selling entity and IIFL Capital and Jefferies are the advisors on the proposed transaction.

According to the March quarter shareholding data, TPG Asia held a 24.7 percent stake in the firm. The promoter shareholding for the quarter was 35.2 percent. FIIs and DIIs held about 12.4 percent and 13.3 percent, respectively. The public shareholding in the firm was around 39.2 percent.

In the January to March quarter, Sai Life Sciences reported revenue of Rs 579 crore, EBITDA margin of 27.2 percent, and a profit of Rs 88 crore.

On June 19, Sai Life Sciences shares closed one percent lower at Rs 730.5 apiece. The 52-week low of the stock is Rs 636 and 52-week high is Rs 808.8. The market capitalisation of the stock is Rs 15,200 crore.

Hyderabad-based Sai Life Sciences provides end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities (NCE) to global pharmaceutical innovator companies and biotechnology firms. The firm made its market debut in December 2024.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.